{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T10:44:45Z","timestamp":1771065885709,"version":"3.50.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,8,21]],"date-time":"2018-08-21T00:00:00Z","timestamp":1534809600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s40263-018-0558-9","type":"journal-article","created":{"date-parts":[[2018,8,21]],"date-time":"2018-08-21T08:12:40Z","timestamp":1534839160000},"page":"905-916","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Efficacy and Safety of Adjunctive Cannabidiol in Patients with Lennox\u2013Gastaut Syndrome: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"32","author":[{"given":"Simona","family":"Lattanzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Brigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Cagnetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugen","family":"Trinka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Silvestrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,21]]},"reference":[{"key":"558_CR1","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1212\/01.wnl.0000252807.38124.a3","volume":"68","author":"D Hirtz","year":"2007","unstructured":"Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. How common are the \u201ccommon\u201d neurologic disorders? Neurology. 2007;68:326\u201337.","journal-title":"Neurology"},{"key":"558_CR2","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1212\/WNL.0000000000000619","volume":"83","author":"C Cagnetti","year":"2014","unstructured":"Cagnetti C, Lattanzi S, Foschi N, Provinciali L, Silvestrini M. Seizure course during pregnancy in catamenial epilepsy. Neurology. 2014;83:339\u201344.","journal-title":"Neurology"},{"key":"558_CR3","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/S0140-6736(95)91208-8","volume":"346","author":"OC Cockerell","year":"1995","unstructured":"Cockerell OC, Johnson AL, Sander JW, Hart YM, Shorvon SD. Remission of epilepsy: results from the national general practice study of epilepsy. Lancet. 1995;346:140\u20134.","journal-title":"Lancet"},{"key":"558_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.seizure.2015.03.003","volume":"27","author":"S Lattanzi","year":"2015","unstructured":"Lattanzi S, Cagnetti C, Foschi N, Provinciali L, Silvestrini M. Lacosamide monotherapy for partial onset seizures. Seizure. 2015;27:71\u20134.","journal-title":"Seizure"},{"key":"558_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/ane.12803","volume":"137","author":"S Lattanzi","year":"2018","unstructured":"Lattanzi S, Cagnetti C, Foschi N, Lorusso A, Provinciali L, Silvestrini M. Eslicarbazepine acetate as adjunctive treatment in partial-onset epilepsy. Acta Neurol Scand. 2018;137:29\u201332.","journal-title":"Acta Neurol Scand"},{"key":"558_CR6","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S1474-4422(08)70292-8","volume":"8","author":"A Arzimanoglou","year":"2009","unstructured":"Arzimanoglou A, French J, Blume WT, Cross JH, Ernst JP, Feucht M, Genton P, Guerrini R, Kluger G, Pellock JM, Perucca E, Wheless JW. Lennox\u2013Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol. 2009;8:82\u201393.","journal-title":"Lancet Neurol"},{"key":"558_CR7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.eplepsyres.2014.11.004","volume":"110","author":"HJ Kim","year":"2015","unstructured":"Kim HJ, Kim HD, Lee JS, Heo K, Kim DS, Kang HC. Long-term prognosis of patients with Lennox\u2013Gastaut syndrome in recent decades. Epilepsy Res. 2015;110:10\u20139.","journal-title":"Epilepsy Res"},{"issue":"Suppl 5","key":"558_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1528-1167.2011.03177.x","volume":"52","author":"PR Camfield","year":"2011","unstructured":"Camfield PR. Definition and natural history of Lennox\u2013Gastaut syndrome. Epilepsia. 2011;52(Suppl 5):3\u20139.","journal-title":"Epilepsia"},{"key":"558_CR9","doi-asserted-by":"publisher","first-page":"e0161660","DOI":"10.1371\/journal.pone.0161660","volume":"11","author":"JH Doring","year":"2016","unstructured":"Doring JH, Lampert A, Hoffmann GF, Ries M. Thirty years of orphan drug legislation and the development of drugs to treat rare seizure conditions: a cross sectional analysis. PLoS One. 2016;11:e0161660.","journal-title":"PLoS One"},{"issue":"suppl 4","key":"558_CR10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/epi.12732","volume":"55","author":"GD Montouris","year":"2014","unstructured":"Montouris GD, Wheless JW, Glauser TA. The efficacy and tolerability of pharmacologic treatment options for Lennox\u2013Gastaut syndrome. Epilepsia. 2014;55(suppl 4):10\u201320.","journal-title":"Epilepsia"},{"key":"558_CR11","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1684\/epd.2011.0479","volume":"13","author":"RO Cersosimo","year":"2011","unstructured":"Cersosimo RO, Bartuluchi M, Fortini S, Soraru A, Pomata H, Caraballo RH. Vagus nerve stimulation: effectiveness and tolerability in 64 paediatric patients with refractory epilepsies. Epileptic Disord. 2011;13:382\u20138.","journal-title":"Epileptic Disord"},{"key":"558_CR12","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/j.0013-9580.2005.48504.x","volume":"46","author":"HC Kang","year":"2005","unstructured":"Kang HC, Kim YJ, Kim DW, Kim HD. Efficacy and safety of the ketogenic diet for intractable childhood epilepsy: Korean multicentric experience. Epilepsia. 2005;46:272\u2013729.","journal-title":"Epilepsia"},{"issue":"suppl 4","key":"558_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/epi.12742","volume":"55","author":"LM Douglass","year":"2014","unstructured":"Douglass LM, Salpekar J. Surgical options for patients with Lennox\u2013Gastaut syndrome. Epilepsia. 2014;55(suppl 4):21\u20138.","journal-title":"Epilepsia"},{"issue":"suppl 4","key":"558_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/epi.12546","volume":"55","author":"EH Kossoff","year":"2014","unstructured":"Kossoff EH, Shields WD. Nonpharmacologic care for patients with Lennox\u2013Gastaut syndrome: ketogenic diets and vagus nerve stimulation. Epilepsia. 2014;55(suppl 4):29\u201333.","journal-title":"Epilepsia"},{"key":"558_CR15","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.braindev.2017.12.012","volume":"40","author":"S Lattanzi","year":"2018","unstructured":"Lattanzi S, Cagnetti C, Matricardi S, Silvestrini M. Palliative non-resective surgery for drug-resistant epilepsy. Brain Dev. 2018;40:512\u20133.","journal-title":"Brain Dev"},{"key":"558_CR16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.14581\/jer.17012","volume":"7","author":"E Perucca","year":"2017","unstructured":"Perucca E. Cannabinoids in the treatment of epilepsy: hard evidence at last? J Epilepsy Res. 2017;7:61\u201376.","journal-title":"J Epilepsy Res"},{"key":"558_CR17","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s13311-015-0377-3","volume":"12","author":"C Ibeas Bih","year":"2015","unstructured":"Ibeas Bih C, Chen T, Nunn AV, Bazelot M, Dallas M, Whalley BJ. Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics. 2015;12:699\u2013730.","journal-title":"Neurotherapeutics"},{"key":"558_CR18","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1124\/jpet.109.159145","volume":"332","author":"NA Jones","year":"2010","unstructured":"Jones NA, Hill AJ, Smith I, Bevan SA, Williams CM, Whalley BJ, Stephens GJ. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J Pharmacol Exp Ther. 2010;332:569\u201377.","journal-title":"J Pharmacol Exp Ther"},{"key":"558_CR19","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/S1474-4422(15)00379-8","volume":"15","author":"O Devinsky","year":"2016","unstructured":"Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, Miller I, Flamini R, Wilfong A, Filloux F, Wong M, Tilton N, Bruno P, Bluvstein J, Hedlund J, Kamens R, Maclean J, Nangia S, Singhal NS, Wilson CA, Patel A, Cilio MR. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016;15:270\u20138.","journal-title":"Lancet Neurol"},{"key":"558_CR20","doi-asserted-by":"publisher","unstructured":"Ru\u017ei\u0107 Ze\u010devi\u0107 D, Foli\u0107 M, Tantoush Z, Radovanovi\u0107 M, Babi\u0107 G, Jankovi\u0107 SM. Investigational cannabinoids in seizure disorders, what have we learned thus far? Expert Opin Investig Drugs. 2018 Jun 6. https:\/\/doi.org\/10.1080\/13543784.2018.1482275 . [Epub ahead of print].","DOI":"10.1080\/13543784.2018.1482275"},{"key":"558_CR21","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.","journal-title":"PLoS Med"},{"key":"558_CR22","first-page":"117","volume":"17","author":"E Niedermeyer","year":"1986","unstructured":"Niedermeyer E. The Lennox\u2013Gastaut syndrome and its frontiers. Clin Electroencephalogr. 1986;17:117\u201326.","journal-title":"Clin Electroencephalogr"},{"key":"558_CR23","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Higgins JPT, Green S, editors. The Cochrane Collaboration, 2011. Available at http:\/\/handbook-5-1.cochrane.org\/ . Accessed October 2017."},{"key":"558_CR24","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"558_CR25","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539\u201358.","journal-title":"Stat Med"},{"key":"558_CR26","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1212\/WNL.0000000000002545","volume":"86","author":"S Lattanzi","year":"2016","unstructured":"Lattanzi S, Cagnetti C, Foschi N, Provinciali L, Silvestrini M. Brivaracetam add-on for refractory focal epilepsy: a systematic review and meta-analysis. Neurology. 2016;86:1344\u201352.","journal-title":"Neurology"},{"key":"558_CR27","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s40263-018-0504-x","volume":"32","author":"S Lattanzi","year":"2018","unstructured":"Lattanzi S, Brigo F, Grillo E, Cagnetti C, Verrotti A, Zaccara G, Silvestrini M. Adjunctive eslicarbazepine acetate in pediatric patients with focal epilepsy: a systematic review and meta-analysis. CNS Drugs. 2018;32:189\u201396.","journal-title":"CNS Drugs"},{"key":"558_CR28","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00415-017-8681-y","volume":"265","author":"S Lattanzi","year":"2018","unstructured":"Lattanzi S, Grillo E, Brigo F, Silvestrini M. Efficacy and safety of perampanel in Parkinson\u2019s disease. A systematic review with meta-analysis. J Neurol. 2018;265:733\u201340.","journal-title":"J Neurol"},{"key":"558_CR29","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1007\/s00415-017-8505-0","volume":"264","author":"S Lattanzi","year":"2017","unstructured":"Lattanzi S, Cagnetti C, Danni M, Provinciali L, Silvestrini M. Oral and intravenous steroids for multiple sclerosis relapse: a systematic review and meta-analysis. J Neurol. 2017;264:1697\u2013704.","journal-title":"J Neurol"},{"key":"558_CR30","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1159\/000462986","volume":"43","author":"S Lattanzi","year":"2017","unstructured":"Lattanzi S, Cagnetti C, Provinciali L, Silvestrini M. How should we lower blood pressure after cerebral hemorrhage? A systematic review and meta-analysis. Cerebrovasc Dis. 2017;43:207\u201313.","journal-title":"Cerebrovasc Dis"},{"key":"558_CR31","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1159\/000488401","volume":"45","author":"S Lattanzi","year":"2018","unstructured":"Lattanzi S, Brigo F, Cagnetti C, Di Napoli M, Silvestrini M. Patent foramen ovale and cryptogenic stroke or transient ischemic attack: to close or not to close? A systematic review and meta-analysis. Cerebrovasc Dis. 2018;45:193\u2013203.","journal-title":"Cerebrovasc Dis"},{"key":"558_CR32","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","volume":"378","author":"O Devinsky","year":"2018","unstructured":"Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham KE. Zuberi SM; GWPCARE3 Study Group. Effect of cannabidiol on drop seizures in the Lennox\u2013Gastaut syndrome. N Engl J Med. 2018;378:1888\u201397.","journal-title":"N Engl J Med"},{"key":"558_CR33","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","volume":"391","author":"EA Thiele","year":"2018","unstructured":"Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, Lyons PD, Taylor A, Roberts C. Sommerville K; GWPCARE4 Study Group. Cannabidiol in patients with seizures associated with Lennox\u2013Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391:1085\u201396.","journal-title":"Lancet"},{"key":"558_CR34","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1212\/WNL.0b013e318232de76","volume":"77","author":"YT Ng","year":"2011","unstructured":"Ng YT, Conry JA, Drummond R, Stolle J. Weinberg MA; OV-1012 Study Investigators. Randomized, phase III study results of clobazam in Lennox\u2013Gastaut syndrome. Neurology. 2011;77:1473\u201381.","journal-title":"Neurology"},{"key":"558_CR35","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1212\/01.wnl.0000303813.95800.0d","volume":"70","author":"T Glauser","year":"2008","unstructured":"Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox\u2013Gastaut syndrome. Neurology. 2008;70:1950\u20138.","journal-title":"Neurology"},{"key":"558_CR36","doi-asserted-by":"publisher","first-page":"e1204","DOI":"10.1212\/WNL.0000000000005254","volume":"90","author":"O Devinsky","year":"2018","unstructured":"Devinsky O, Patel AD, Thiele EA, Wong MH, Appleton R, Harden CL, Greenwood S, Morrison G, Sommerville K, GWPCARE1 Part A Study Group. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology. 2018;90:e1204\u201311.","journal-title":"Neurology."},{"key":"558_CR37","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/epi.13060","volume":"56","author":"AL Geffrey","year":"2015","unstructured":"Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug\u2013drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015;56:1246\u201351.","journal-title":"Epilepsia."},{"key":"558_CR38","unstructured":"Thiele EA, Devinsky O, Checketts D, Knappertz V. Cannabidiol (CBD) treatment responders analysis in patients with Lennox\u2013Gastaut syndrome (LGS) on and off clobazam (CLB). The American Epilepsy Society Annual Meeting; Washington, DC; December 1\u20135, 2017. Abst. 1.436. Available at: https:\/\/www.aesnet.org\/meetings_events\/annual_meeting_abstracts\/view\/381224 (Accessed on July, 2018)]."},{"key":"558_CR39","unstructured":"US Department of Health and Human Services. Guidance for industry. Drug-induced liver injury: premarketing clinical evaluation. 2009. https:\/\/www.fda.gov\/downloads\/Guidances\/UCM174090.pdf . Accessed Jun 11, 2018."},{"key":"558_CR40","doi-asserted-by":"publisher","unstructured":"Stockings E, Zagic D, Campbell G, Weier M, Hall WD, Nielsen S, Herkes GK, Farrell M, Degenhardt L. Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence. J Neurol Neurosurg Psychiatry. 2018 Mar 6. https:\/\/doi.org\/10.1136\/jnnp-2017-317168 . [Epub ahead of print].","DOI":"10.1136\/jnnp-2017-317168"},{"key":"558_CR41","doi-asserted-by":"crossref","unstructured":"Gloss D, Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst Rev. 2014;(3):CD009270.","DOI":"10.1002\/14651858.CD009270.pub3"},{"key":"558_CR42","doi-asserted-by":"publisher","unstructured":"Szaflarski JP, Bebin EM, Comi AM, Patel AD, Joshi C, Checketts D, Beal JC, Laux LC, De Boer LM, Wong MH, Lopez M, Devinsky O, Lyons PD, Zentil PP, Wechsler R; CBD EAP study group. Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: expanded access program results. Epilepsia. 2018 Jul 12. https:\/\/doi.org\/10.1111\/epi.14477 . [Epub ahead of print].","DOI":"10.1111\/epi.14477"},{"key":"558_CR43","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","volume":"376","author":"O Devinsky","year":"2017","unstructured":"Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, Scheffer IE, Thiele EA, Wright S, Cannabidiol in Dravet Syndrome Study Group. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376:2011\u201320.","journal-title":"N Engl J Med"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-018-0558-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-018-0558-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-018-0558-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,8]],"date-time":"2020-11-08T01:59:11Z","timestamp":1604800751000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-018-0558-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,21]]},"references-count":43,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["558"],"URL":"https:\/\/doi.org\/10.1007\/s40263-018-0558-9","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,21]]},"assertion":[{"value":"21 August 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding was received to conduct this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Simona Lattanzi, Claudia Cagnetti and Mauro Silvestrini have no conflicts of interest directly relevant to the content of this study. Francesco Brigo acted as a consultant for Eisai. Eugen Trinka received speaker\u2019s honoraria from UCB, Biogen, Gerot-Lannach, Bial, Eisai, Takeda, Newbridge, Sunovion Pharmaceuticals Inc., LivaNova and Novartis; consultancy funds from UCB, Biogen, Gerot-Lannach, Bial, Eisai, Takeda, Newbridge, GW Pharmaceuticals, Sunovion Pharmaceuticals Inc., and Novartis; and directorship funds from Neuroconsult GmbH. E. Trinka\u2019s Institution received grants from Biogen, Red Bull, Merck, UCB, European Union, FWF \u00d6sterreichischer Fond zur Wissenschaftsf\u00f6rderung, and Bundesministerium f\u00fcr Wissenschaft und Forschung.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}